1. Home
  2. ENSC vs PTIX Comparison

ENSC vs PTIX Comparison

Compare ENSC & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENSC
  • PTIX
  • Stock Information
  • Founded
  • ENSC 2003
  • PTIX 1994
  • Country
  • ENSC United States
  • PTIX United States
  • Employees
  • ENSC N/A
  • PTIX N/A
  • Industry
  • ENSC Biotechnology: Pharmaceutical Preparations
  • PTIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ENSC Health Care
  • PTIX Health Care
  • Exchange
  • ENSC Nasdaq
  • PTIX Nasdaq
  • Market Cap
  • ENSC 6.4M
  • PTIX 6.3M
  • IPO Year
  • ENSC N/A
  • PTIX 2016
  • Fundamental
  • Price
  • ENSC $2.55
  • PTIX $3.05
  • Analyst Decision
  • ENSC
  • PTIX
  • Analyst Count
  • ENSC 0
  • PTIX 0
  • Target Price
  • ENSC N/A
  • PTIX N/A
  • AVG Volume (30 Days)
  • ENSC 174.0K
  • PTIX 108.9K
  • Earning Date
  • ENSC 11-11-2025
  • PTIX 11-13-2025
  • Dividend Yield
  • ENSC N/A
  • PTIX N/A
  • EPS Growth
  • ENSC N/A
  • PTIX N/A
  • EPS
  • ENSC N/A
  • PTIX N/A
  • Revenue
  • ENSC $7,413,722.00
  • PTIX N/A
  • Revenue This Year
  • ENSC N/A
  • PTIX N/A
  • Revenue Next Year
  • ENSC $1,354.55
  • PTIX N/A
  • P/E Ratio
  • ENSC N/A
  • PTIX N/A
  • Revenue Growth
  • ENSC 415.58
  • PTIX N/A
  • 52 Week Low
  • ENSC $1.62
  • PTIX $2.25
  • 52 Week High
  • ENSC $14.67
  • PTIX $15.26
  • Technical
  • Relative Strength Index (RSI)
  • ENSC 64.39
  • PTIX 40.87
  • Support Level
  • ENSC $2.19
  • PTIX $2.93
  • Resistance Level
  • ENSC $2.50
  • PTIX $3.77
  • Average True Range (ATR)
  • ENSC 0.21
  • PTIX 0.28
  • MACD
  • ENSC 0.01
  • PTIX -0.07
  • Stochastic Oscillator
  • ENSC 64.53
  • PTIX 10.66

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

About PTIX Protagenic Therapeutics Inc.

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Share on Social Networks: